158 related articles for article (PubMed ID: 38423295)
1. The Prevalence Of Osteoporosis Is Low in Adult Cutaneous Mastocytosis Patients.
Degboé Y; Severino-Freire M; Couture G; Apoil PA; Gaudenzio N; Hermine O; Ruyssen-Witrand A; Paul C; Laroche M; Constantin A; Livideanu CB
J Allergy Clin Immunol Pract; 2024 May; 12(5):1306-1312. PubMed ID: 38423295
[TBL] [Abstract][Full Text] [Related]
2. Higher prevalence of vertebral fractures in systemic mastocytosis, but not in cutaneous mastocytosis and idiopathic mast cell activation syndrome.
Degboé Y; Eischen M; Apoil PA; Mailhol C; Dubreuil P; Hermine O; Paul C; Bulai Livideanu C; Laroche M
Osteoporos Int; 2019 Jun; 30(6):1235-1241. PubMed ID: 30847528
[TBL] [Abstract][Full Text] [Related]
3. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
4. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
[TBL] [Abstract][Full Text] [Related]
5. Frequency of isolated cutaneous involvement in adult mastocytosis: a cohort study.
Fradet M; Negretto M; Tournier E; Laurent C; Apoil PA; Evrard S; Degboe Y; Del Mas V; Lamant L; Dubreuil P; Laroche M; Mailhol C; Hermine O; Paul C; Bulai Livideanu C
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1713-1718. PubMed ID: 31009132
[TBL] [Abstract][Full Text] [Related]
6. The presence of mast cell clonality in patients with unexplained anaphylaxis.
Gülen T; Hägglund H; Sander B; Dahlén B; Nilsson G
Clin Exp Allergy; 2014 Sep; 44(9):1179-87. PubMed ID: 25039926
[TBL] [Abstract][Full Text] [Related]
7. Mastocytosis and related entities: a practical roadmap.
Beyens M; Elst J; van der Poorten ML; Van Gasse A; Toscano A; Verlinden A; Vermeulen K; Maes MB; Oude Elberink JNGH; Ebo D; Sabato V
Acta Clin Belg; 2023 Aug; 78(4):325-335. PubMed ID: 36259506
[TBL] [Abstract][Full Text] [Related]
8. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and risk factors for fragility fracture in systemic mastocytosis.
Degboé Y; Eischen M; Nigon D; Apoil PA; Mailhol C; Tournier E; Laurent C; Hanssens K; Hermine O; Paul C; Laroche M; Bulai-Livideanu C
Bone; 2017 Dec; 105():219-225. PubMed ID: 28919366
[TBL] [Abstract][Full Text] [Related]
10. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
11. Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic work-up of 38 patients.
Van den Poel B; Kochuyt AM; Del Biondo E; Dewaele B; Lierman E; Tousseyn T; de Hertogh G; Vandenberghe P; Boeckx N
Acta Clin Belg; 2017 Apr; 72(2):123-129. PubMed ID: 28262030
[TBL] [Abstract][Full Text] [Related]
12. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis.
Álvarez-Twose I; Jara-Acevedo M; Morgado JM; García-Montero A; Sánchez-Muñoz L; Teodósio C; Matito A; Mayado A; Caldas C; Mollejo M; Orfao A; Escribano L
J Allergy Clin Immunol; 2016 Jan; 137(1):168-178.e1. PubMed ID: 26100086
[TBL] [Abstract][Full Text] [Related]
13. Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin.
Fuchs D; Kilbertus A; Kofler K; von Bubnoff N; Shoumariyeh K; Zanotti R; Bonadonna P; Scaffidi L; Doubek M; Elberink HO; Span LFR; Hermine O; Elena C; Benvenuti P; Yavuz AS; Brockow K; Zink A; Aberer E; Gorska A; Romantowski J; Hadzijusufovic E; Fortina AB; Caroppo F; Perkins C; Illerhaus A; Panse J; Vucinic V; Jawhar M; Sabato V; Triggiani M; Parente R; Bergström A; Breynaert C; Gotlib J; Reiter A; Hartmann K; Niedoszytko M; Arock M; Kluin-Nelemans HC; Sperr WR; Greul R; Valent P
J Allergy Clin Immunol Pract; 2021 Apr; 9(4):1705-1712.e4. PubMed ID: 33346151
[TBL] [Abstract][Full Text] [Related]
14. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
[TBL] [Abstract][Full Text] [Related]
16. Hypertryptasemia and Mast Cell-Related Disorders in Severe Osteoporotic Patients.
Carosi G; Guabello G; Longhi M; Grifoni F; Passeri E; Corbetta S
Mediators Inflamm; 2020; 2020():5785378. PubMed ID: 33144848
[TBL] [Abstract][Full Text] [Related]
17. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms.
Alvarez-Twose I; González-de-Olano D; Sánchez-Muñoz L; Matito A; Jara-Acevedo M; Teodosio C; García-Montero A; Morgado JM; Orfao A; Escribano L
Int Arch Allergy Immunol; 2012; 157(3):275-80. PubMed ID: 22042301
[TBL] [Abstract][Full Text] [Related]
18. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
19. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis.
González-de-Olano D; Alvarez-Twose I; Vega A; Orfao A; Escribano L
Immunotherapy; 2011 May; 3(5):637-51. PubMed ID: 21554093
[TBL] [Abstract][Full Text] [Related]
20. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.
Horny HP; Sotlar K; Sperr WR; Valent P
J Clin Pathol; 2004 Jun; 57(6):604-8. PubMed ID: 15166264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
